Last reviewed · How we verify
Halobetasol Topical Foam
Halobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Halobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema.
At a glance
| Generic name | Halobetasol Topical Foam |
|---|---|
| Also known as | HBP Foam |
| Sponsor | Mayne Pharma International Pty Ltd |
| Drug class | Topical corticosteroid (Class I, super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Halobetasol is a Class I (super-potent) topical corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of cutaneous inflammation. The foam formulation provides enhanced penetration and coverage for inflammatory skin conditions.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Psoriasis
- Eczema
- Lichen planus
- Other corticosteroid-responsive skin conditions
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
- Perioral dermatitis
Key clinical trials
- Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (PHASE4)
- Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halobetasol Topical Foam CI brief — competitive landscape report
- Halobetasol Topical Foam updates RSS · CI watch RSS
- Mayne Pharma International Pty Ltd portfolio CI